D
D. Seimetz
Researcher at University of Hamburg
Publications - 12
Citations - 636
D. Seimetz is an academic researcher from University of Hamburg. The author has contributed to research in topics: Catumaxomab & Trifunctional antibody. The author has an hindex of 7, co-authored 12 publications receiving 560 citations.
Papers
More filters
Journal ArticleDOI
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
TL;DR: Catumaxomab is the first trAb and the first drug worldwide to be approved specifically for the treatment of MA and is in clinical trials in a number of other indications including ovarian and gastric cancer.
Journal ArticleDOI
Catumaxomab: clinical development and future directions.
R. Linke,Anke Klein,D. Seimetz +2 more
TL;DR: This review focuses on the clinical development of catumaxomab, the first substance worldwide with a regulatory label for the treatment of malignant ascites due to epithelial carcinomas, and indicates future directions.
Journal ArticleDOI
Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
Marion G. Ott,Frederik Marmé,Gerhard Moldenhauer,Horst Lindhofer,M. Hennig,Rolf Spannagl,Mirko M. Essing,R. Linke,D. Seimetz +8 more
TL;DR: HAMA development may be a biomarker for catumaxomab response and patients who developed HAMAs sooner derived greater benefit from catumxomab treatment.
Journal ArticleDOI
The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting.
Djordje Atanackovic,Henrike Reinhard,Sabrina Meyer,Stefanie Spöck,Tobias Grob,Tim Luetkens,Sara Yousef,Yanran Cao,York Hildebrandt,Julia Templin,Katrin Bartels,Nesrine Lajmi,Heribert Stoiber,Nicolaus Kröger,Judith Atz,D. Seimetz,Jakob R. Izbicki,Carsten Bokemeyer +17 more
TL;DR: The findings suggest that catumaxomab exerts its clinical effects by activating peripheral T cells, redistributing effector T cells from the blood into peripheral tissues, expanding and shaping of the pre-existing EpCAM-specific T-cell repertoire, and spreading of anti-tumor immunity to different tumor antigens.
Journal ArticleDOI
The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study
Markus M. Heiss,Michael A. Ströhlein,Carsten Bokemeyer,Dirk Arnold,Simon L. Parsons,D. Seimetz,Horst Lindhofer,Elisabeth Schulze,Michael Hennig +8 more
TL;DR: OS was significantly improved after catumaxomab treatment in patients with malignant ascites and an RLC > 13% at baseline was a significant prognostic biomarker.